Elagolix sodium

• CAT Number: M000101
• CAS Number: 832720-36-2
• Molecular Formula: C32H29F5N3NaO5
• Molecular Weight: 653.57
• Purity: 98%
• Synonyms: sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
• Target: GNRHR
• Target Protein: P30968
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 0.25 nM (GnRHR)
• InChI: InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
• InChIKey: DQYGXRQUFSRDCH-UQIIZPHYSA-M
• SMILES: CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]

Elagolix sodium（Cat No.:M000101）is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist used to manage pain associated with endometriosis and heavy menstrual bleeding due to uterine fibroids. By blocking GnRH receptors in the pituitary gland, Elagolix reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased production of estrogen. This suppression of estrogen helps alleviate symptoms like pelvic pain, menstrual cramps, and excessive bleeding. Its oral administration and targeted action make Elagolix an effective and convenient option for women managing hormone-driven gynecological conditions.

Reference

[1]. Kim SM, et al. Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. J Med Chem. 2016 Oct 13;59(19):9150-9172. Epub 2016 Sep 27.
[Content Brief]

[2]. Chen C, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonis
[Content Brief]